Does the media prefer RYTM or COAG?

In the previous week, Rhythm Pharmaceuticals had 12 more articles in the media than Hemab Therapeutics. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 5 mentions for Hemab Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.38 beat Hemab Therapeutics' score of 0.15 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, SRRK or COAG?

Scholar Rock is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Hemab Therapeutics N/A N/A N/A -$24.78 N/A

Is SRRK or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Hemab Therapeutics N/A N/A N/A

Does the media favor SRRK or COAG?

In the previous week, Scholar Rock had 27 more articles in the media than Hemab Therapeutics. MarketBeat recorded 32 mentions for Scholar Rock and 5 mentions for Hemab Therapeutics. Scholar Rock's average media sentiment score of 0.78 beat Hemab Therapeutics' score of 0.15 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 13 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CGON or COAG?

In the previous week, CG Oncology had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for CG Oncology and 5 mentions for Hemab Therapeutics. CG Oncology's average media sentiment score of 0.56 beat Hemab Therapeutics' score of 0.15 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to COAG or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 5 mentions for Hemab Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Hemab Therapeutics' score of 0.15 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COAG or TVTX?

In the previous week, Travere Therapeutics had 32 more articles in the media than Hemab Therapeutics. MarketBeat recorded 37 mentions for Travere Therapeutics and 5 mentions for Hemab Therapeutics. Travere Therapeutics' average media sentiment score of 0.34 beat Hemab Therapeutics' score of 0.15 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 16 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hemab Therapeutics (COAG) Competitors

$41.19 -0.03 (-0.07%)

As of 09/18/2026 04:00 PM Eastern

Compare

COAG vs. RYTM, SRRK, CGON, MIRM, and TVTX

Should you buy Hemab Therapeutics stock or one of its competitors? Hemab Therapeutics's main competitors and comparable companies include Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Hemab Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Hemab Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Hemab Therapeutics' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Hemab Therapeutics	N/A	N/A	N/A

Hemab Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Rhythm Pharmaceuticals currently has a consensus target price of $140.67, indicating a potential upside of 43.96%. Hemab Therapeutics has a consensus target price of $51.40, indicating a potential upside of 24.79%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Rhythm Pharmaceuticals had 12 more articles in the media than Hemab Therapeutics. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 5 mentions for Hemab Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.38 beat Hemab Therapeutics' score of 0.15 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rhythm Pharmaceuticals beats Hemab Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Hemab Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, Scholar Rock had 27 more articles in the media than Hemab Therapeutics. MarketBeat recorded 32 mentions for Scholar Rock and 5 mentions for Hemab Therapeutics. Scholar Rock's average media sentiment score of 0.78 beat Hemab Therapeutics' score of 0.15 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	13 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Hemab Therapeutics	N/A	N/A	N/A

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Scholar Rock is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Scholar Rock presently has a consensus price target of $66.00, suggesting a potential upside of 41.48%. Hemab Therapeutics has a consensus price target of $51.40, suggesting a potential upside of 24.79%. Given Scholar Rock's stronger consensus rating and higher probable upside, equities analysts clearly believe Scholar Rock is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.00
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Scholar Rock beats Hemab Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Hemab Therapeutics (NASDAQ:COAG) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, CG Oncology had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for CG Oncology and 5 mentions for Hemab Therapeutics. CG Oncology's average media sentiment score of 0.56 beat Hemab Therapeutics' score of 0.15 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology presently has a consensus price target of $87.78, suggesting a potential upside of 17.63%. Hemab Therapeutics has a consensus price target of $51.40, suggesting a potential upside of 24.79%. Given Hemab Therapeutics' higher probable upside, analysts plainly believe Hemab Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Hemab Therapeutics has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Hemab Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Hemab Therapeutics	N/A	N/A	N/A

Hemab Therapeutics has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,637.21	-$160.99M	-$2.69	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Summary

CG Oncology beats Hemab Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Hemab Therapeutics compare to Mirum Pharmaceuticals?

Hemab Therapeutics (NASDAQ:COAG) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 5 mentions for Hemab Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Hemab Therapeutics' score of 0.15 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A

Hemab Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Hemab Therapeutics' return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Hemab Therapeutics presently has a consensus price target of $51.40, suggesting a potential upside of 24.79%. Mirum Pharmaceuticals has a consensus price target of $137.31, suggesting a potential upside of 49.53%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Mirum Pharmaceuticals beats Hemab Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to Travere Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Hemab Therapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Hemab Therapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Hemab Therapeutics has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Travere Therapeutics	$490.73M	12.06	-$25.55M	-$0.46	N/A

Hemab Therapeutics presently has a consensus target price of $51.40, indicating a potential upside of 24.79%. Travere Therapeutics has a consensus target price of $68.00, indicating a potential upside of 8.35%. Given Hemab Therapeutics' higher probable upside, equities analysts clearly believe Hemab Therapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Travere Therapeutics had 32 more articles in the media than Hemab Therapeutics. MarketBeat recorded 37 mentions for Travere Therapeutics and 5 mentions for Hemab Therapeutics. Travere Therapeutics' average media sentiment score of 0.34 beat Hemab Therapeutics' score of 0.15 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	16 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Travere Therapeutics beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Hemab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COAG vs. The Competition

Export

Metric	Hemab Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.92B	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-1.66	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	N/A	15.45	10.46	6.33
Net Income	N/A	-$22.86M	$3.49B	$358.33M
7 Day Performance	4.54%	-1.21%	0.59%	1.12%
1 Month Performance	-14.54%	-3.29%	-1.74%	-2.39%
1 Year Performance	N/A	37.74%	18.13%	5.35%

Hemab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COAG Hemab Therapeutics	3.1941 of 5 stars	$41.19 -0.1%	$51.40 +24.8%	N/A	$1.92B	N/A	N/A	59	News Coverage High Trading Volume
RYTM Rhythm Pharmaceuticals	2.7622 of 5 stars	$104.71 +2.5%	$141.12 +34.8%	+1.7%	$7.18B	$189.76M	N/A	414	News Coverage Analyst Forecast
SRRK Scholar Rock	3.6662 of 5 stars	$55.41 -0.5%	$58.77 +6.1%	+51.3%	$6.75B	N/A	N/A	289	Analyst Downgrade Analyst Revision Gap Down
CGON CG Oncology	2.8453 of 5 stars	$72.35 +0.5%	$87.78 +21.3%	+102.2%	$6.41B	$4.04M	N/A	142	News Coverage
MIRM Mirum Pharmaceuticals	3.0298 of 5 stars	$98.22 -2.4%	$137.31 +39.8%	+23.5%	$6.38B	$521.31M	N/A	433

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COAG) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemab Therapeutics (COAG) Competitors

COAG vs. RYTM, SRRK, CGON, MIRM, and TVTX

How does Hemab Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Hemab Therapeutics compare to Scholar Rock?

Summary

How does Hemab Therapeutics compare to CG Oncology?

Summary

How does Hemab Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Hemab Therapeutics compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemab Therapeutics (COAG) Competitors

COAG vs. RYTM, SRRK, CGON, MIRM, and TVTX

How does Hemab Therapeutics compare to Rhythm Pharmaceuticals?

Is RYTM or COAG more profitable?

Which has better earnings & valuation, RYTM or COAG?

Do analysts recommend RYTM or COAG?

Does the media prefer RYTM or COAG?

Summary

How does Hemab Therapeutics compare to Scholar Rock?

Does the media favor SRRK or COAG?

Is SRRK or COAG more profitable?

Do insiders & institutionals hold more shares of SRRK or COAG?

Which has preferable earnings and valuation, SRRK or COAG?

Do analysts rate SRRK or COAG?

Summary

How does Hemab Therapeutics compare to CG Oncology?

Do institutionals & insiders hold more shares of CGON or COAG?

Does the media prefer CGON or COAG?

Do analysts prefer CGON or COAG?

Is CGON or COAG more profitable?

Which has stronger earnings and valuation, CGON or COAG?

Summary

How does Hemab Therapeutics compare to Mirum Pharmaceuticals?

Does the media refer more to COAG or MIRM?

Which has higher earnings & valuation, COAG or MIRM?

Is COAG or MIRM more profitable?

Do analysts prefer COAG or MIRM?

Summary

How does Hemab Therapeutics compare to Travere Therapeutics?

Is COAG or TVTX more profitable?

Which has better valuation & earnings, COAG or TVTX?

Do analysts prefer COAG or TVTX?

Does the media prefer COAG or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools